Fonar retains investment banker

Article

Fonar has retained an investment banker to assess its MRI operations, the Melville, NY, company announced on March 3. While Fonar executives aren’t providing any details about the firm’s intentions, the company did say that it plans to make

Fonar has retained an investment banker to assess its MRI operations, the Melville, NY, company announced on March 3. While Fonar executives aren’t providing any details about the firm’s intentions, the company did say that it plans to make “the investment community aware of the new MRI technologies amassed by Fonar from its recent heavy investment in R&D that are expected to enhance shareholder value.”

It’s unclear whether that awareness could translate into a divestiture of the MRI business. Fonar for the last several years has been attempting a comeback in MRI, but the vendor has been stymied by a lack of market interest in its new line of Quad scanners. For the company’s most recent financial period, Fonar recorded only $602,000 in product sales (SCAN 3/3/99).

On the other hand, Fonar has been successful in making acquisitions to increase its healthcare services business, which has been the engine behind the firm’s revenue growth. The company said its retention of an investment banker will help the firm evaluate prospective acquisitions.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.